Leprosy now: Epidemiology, progress, challenges, and research gaps

The Lancet Infectious Diseases

Volumn 11, Issue 6, 2011, Pages 464-470

  Rodrigues, Laura C ^a   Lockwood, Diana N J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CLOFAZIMINE; CULTURE FILTRATE PROTEIN 10; DAPSONE; EARLY SECRETORY ANTIGENIC TARGET 6; MINOCYCLINE; OFLOXACIN; PREDNISOLONE; RIFAMPICIN; STEROID; THALIDOMIDE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIAL TRANSMISSION; BCG VACCINATION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE SURVEILLANCE; DNA SEQUENCE; EARLY DIAGNOSIS; ERYTHEMA NODOSUM LEPROSUM; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; IMMUNE RESPONSE; INFECTION RISK; LEPROMATOUS LEPROSY; LEPROMIN TEST; LEPROSY; LEPROSY CONTROL; LEPROSY EPIDEMIOLOGY; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; NEUROPATHY; NONHUMAN; PAUCIBACILLARY LEPROSY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

BACTERIAL VACCINES; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MYCOBACTERIUM LEPRAE; WORLD HEALTH;

EID: 79956279666     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70006-8     Document Type: Review

References (65)

1. The Millennium Development Goals (MDGs) and Disability United Nations Enable, (accessed Jan 25, 2010). http://www.un.org/disabilities/default.asp?id=1470.
2. Merle CS, Cunha SS, Rodrigues LC BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010, 9:209-222.
3. Enhanced global strategy for further reducing the disease burden due to leprosy (plan period: 2011-2015) 2008, WHO, World Health Organization Regional Office for South-East Asia, New Delhi.
4. Hatta M, van Beers SM, Madjid B, Djumadi A, de Wit MY, Klatser PR Distribution and persistence of Mycobacterium leprae nasal carriage among a population in which leprosy is endemic in Indonesia. Trans R Soc Trop Med Hyg 1995, 89:381-385.
5. Senior K Stigma, chemoprophylaxis, and leprosy control. Lancet Infect Dis 2009, 9:10.
6. Report of the Tenth Meeting of the WHO Technical Advisory Group on Leprosy Control 2009, WHO Technical Advisory Group on Leprosy Control, World Health Organization Regional Office for South-East Asia, New Delhi.
7. Arungiri S, et al. Detection of mutations in folp1, rpoB and gyrA genes of M. leprae by PCR-direct sequencing-a rapid tool for screening drug resistance in leprosy. Lepr Rev (in press).
8. Moet FJ, Meima A, Oskam L, Richardus JH Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. Lepr Rev 2004, 75:310-326.
9. Monot M, Honore N, Garnier T, et al. Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet 2009, 41:1282-1289.
10. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med 2009, 361:2609-2618.
11. Gillis T, Vissa V, Matsuoka M, et al. Characterisation of short tandem repeats for genotyping Mycobacterium leprae. Lepr Rev 2009, 80:250-260.
12. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL The continuing challenges of leprosy. Clin Microbiol Rev 2006, 19:338-381.
13. Feasey N, Wansbrough-Jones M, Mabey DC, Solomon AW Neglected tropical diseases. Br Med Bull 2010, 93:179-200.
14. World Health Assembly resolution 1991 World Health Assembly, (accessed Jan 25, 2010). http://www.who.int/lep/strategy/wha/en/index.html.
15. Burki T Old problems still mar fight against ancient disease. Lancet 2009, 373:287-288.
16. We can end poverty 2015: Millennium Development Goals UN, (accessed Jan 25, 2010). http://www.un.org/millenniumgoals.
17. Convention on the rights of persons with disabilities UN Enable, (accessed Jan 25, 2010). http://www.un.org/disabilities/default.asp?id=150.
18. Resolution 8/13: elimination of discrimination against persons affected by leprosy and their family members Human Rights Council, (accessed Jan 25, 2010). http://ap.ohchr.org/documents/E/HRC/resolutions/A_HRC_RES_8_13.pdf.
19. The Millennium Development Goals (MDGs): unrealistic and unattainable because MDG implementation policies advance the interests of the rich world at the expense of the poor? The Leprosy Mission Ireland, (accessed Jan 25, 2010). http://www.leprosymission.ie/media/8986_MDGreportPublishedAug09.pdf.
20. Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec 2008, 83:293-300. Anon.
21. Global leprosy situation, 2009. Wkly Epidemiol Rec 2009, 84:333-340. Anon.
22. Weekly epidemiological record WHO, (accessed April 12, 2011). http://www.who.int/wer/en/.
23. RIPSA, (accessed April 28, 2011). http://tabnet.datasus.gov.br/cgi/deftohtm.exe?idb2006/d09.def.
24. Global leprosy situation, 2008 (additional information). Wkly Epidemiol Rec 2008, 83:459. Anon.
25. Van Brakel WH, Officer A Approaches and tools for measuring disability in low and middle-income countries. Lepr Rev 2008, 79:50-64.
26. Truman RW, Singh P, Sharma R, et al. Probable zoonotic leprosy in the southern United States. N Engl J Med 2011, 364:1626-1633.
27. Truman RW, Fine PEM 'Environmental' sources of Mycobacterium leprae: issues and evidence. Lepr Rev 2010, 81:89-95.
28. Job CK, Jayakumar J, Kearney M, Gillis TP Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg 2008, 78:518-521.
29. Cole ST, Supply P, Honore N Repetitive sequences in Mycobacterium leprae and their impact on genome plasticity. Lepr Rev 2001, 72:449-461.
30. Gomez-Valero L, Rocha EP, Latorre A, Silva FJ Reconstructing the ancestor of Mycobacterium leprae: the dynamics of gene loss and genome reduction. Genome Res 2007, 17:1178-1185.
31. Katoch VM, Lavania M, Chauhan DS, Sharma R, Katoch K Hirawati Recent advances in molecular biology of leprosy. Indian J Lepr 2007, 79:151-166.
32. Matsuoka M, Gonzalez AV, Estrada I, Carreno-Martinez C, Fafutis-Morris M Various genotypes of Mycobacterium leprae from Mexico reveal distinct geographic distribution. Lepr Rev 2009, 80:322-326.
33. Ridley DS, Jopling WH A classification of leprosy for research purposes. Lepr Rev 1962, 33:119-128.
34. Van Brakel WH, Nicholls PG, Das L, et al. The INFIR Cohort Study: assessment of sensory and motor neuropathy in leprosy at baseline. Lepr Rev 2005, 76:277-295.
35. Lockwood DN, Sarno E, Smith WC Classifying leprosy patients-searching for the perfect solution?. Lepr Rev 2007, 78:317-320.
36. Boku N, Lockwood DN, Balagon MV, et al. Impacts of the diagnosis of leprosy and of visible impairments amongst people affected by leprosy in Cebu, the Philippines. Lepr Rev 2010, 81:111-120.
37. Saunderson P The epidemiology of reactions and nerve damage. Lepr Rev 2000, 71:S106-S110.
38. Khambati FA, Shetty VP, Ghate SD, Capadia GD Sensitivity and specificity of nerve palpation, monofilament testing and voluntary muscle testing in detecting peripheral nerve abnormality, using nerve conduction studies as gold standard; a study in 357 patients. Lepr Rev 2009, 80:34-50.
39. Smith WC, Nicholls PG, Das L, et al. Predicting neuropathy and reactions in leprosy at diagnosis and before incident events-results from the INFIR cohort study. PLoS Negl Trop Dis 2009, 3:e500.
40. Leprosy as a neurological disease. Lancet Neurol 2009, 8:217. The Lancet Neurology.
41. Walker SL, Nicholls PG, Dhakal S, Hawksworth RA, Mahat K, Lockwood DNJ A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous Normal saline and oral prednisolone in individuals with leprosy Type 1 reactions and/or nerve function impairment. PLOS Negl Trop Dis 2011, 5:e1041.
42. van Veen NH, Nicholls PG, Smith WC, Richardus JH Corticosteroids for treating nerve damage in leprosy. A Cochrane review. Lepr Rev 2008, 79:361-371.
43. Rao PS, Sugamaran DS, Richard J, Smith WC Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev 2006, 77:25-33.
44. Van Brakel W, Cross H, Deepak S, et al. Review of leprosy research evidence (2002-2009) and implications for current policy and practice. Lepr Rev 2010, 81:228-275. ILEP Technical Commission.
45. Van Brakel WH, Saunderson P, Shetty V, et al. International workshop on neuropathology in leprosy-consensus report. Lepr Rev 2007, 78:416-433.
46. Pocaterra L, Jain S, Reddy R, et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 2006, 74:868-879.
47. Van Veen NHJ, Lockwood DNJ, van Brakel WH, Ramirez JJ, Richardus JH Interventions for erythema nodosum leprosum. Cochrane Database Syst Rev 2009, 3. CD006949.
48. Walker SL, Waters MF, Lockwood DN The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 2007, 78:197-215.
49. Ustianowski AP, Lawn SD, Lockwood DN Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis 2006, 6:350-360.
50. Sarno EN, Illarramendi X, Nery JA, et al. HIV-M. leprae interaction: can HAART modify the course of leprosy?. Public Health Rep 2008, 123:206-212.
51. Talhari C, Mira MT, Massone C, et al. Leprosy and HIV coinfection: a clinical, pathological, immunological, and therapeutic study of a cohort from a Brazilian referral center for infectious diseases. J Infect Dis 2010, 202:345-354.
52. Lawn SD, Wood C, Lockwood DN Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin Infect Dis 2003, 36:e5-e6.
53. Deps PD, Lockwood DN Leprosy occurring as immune reconstitution syndrome. Trans R Soc Trop Med Hyg 2008, 102:966-968.
54. Deps P, Lockwood DN Leprosy presenting as immune reconstitution inflammatory syndrome: proposed definitions and classification. Lepr Rev 2010, 81:59-68.
55. Kaimal S, Thappa DM Relapse in leprosy. Indian J Dermatol Venereol Leprol 2009, 75:126-135.
56. Nicholls PG, Ross L, Smith WC Promoting early detection in leprosy-a literature review to identify proven and potential interventions addressing patient-related delay. Lepr Rev 2006, 77:298-310.
57. Meima A, Saunderson PR, Gebre S, Desta K, van Oortmarssen GJ, Habbema JD Factors associated with impairments in new leprosy patients: the AMFES cohort. Lepr Rev 1999, 70:189-203.
58. Richardus JH, Meima A, Croft RP, Habbema JD Case detection, gender and disability in leprosy in Bangladesh: a trend analysis. Lepr Rev 1999, 70:160-173.
59. Richardus JH, Habbema JD The impact of leprosy control on the transmission of M. leprae: is elimination being attained?. Lepr Rev 2007, 78:330-337.
60. Sekar B Recent advances in immunodiagnosis of leprosy. Indian J Lepr 2007, 79:85-106.
61. Moet FJ, Pahan D, Oskam L, Richardus JH Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ 2008, 336:761-764.
62. Schuring RP, Richardus JH, Pahan D, Oskam L Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. Vaccine 2009, 27:7125-7128.
63. Duppre NC, Camacho LA, da Cunha SS, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg 2008, 102:631-638.
64. Gillis T Is there a role for a vaccine in leprosy control?. Lepr Rev 2007, 78:338-342.
65. Raman VS, O'Donnell J, Bailor HR, et al. Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection. Infect Immun 2009, 77:5623-5630.